HSPA9 and breast carcinoma: Previously, using the wild-type p53 possessing MCF-7 breast carcinoma and U2OS osteosarcoma cells, a library of 12,000 molecules was screened to identify potential mortalin–p53 interaction disruptors based on the shift in mortalin staining pattern from perinuclear to pan-cytoplasmic and the stabilization, accumulation and nuclear enrichment of p53.